Previous issue | Volume 89 | ESPE2018 | Next issue

57th Annual ESPE

Athens, Greece
27 Sep 2018 - 29 Sep 2018

Card image cap
ESPE 2018 57th European Society for Paediatric Endocrinology Annual Meeting 27-29 September 2018 Athens, Greece

Poster Presentations

Pituitary, Neuroendocrinology and Puberty P1

A 7-Year Update Report of a National, Interdisciplinary Endeavour to Improve Outcomes for Children and Young People Under 19 Years of Age with Hypothalamic Pituitary Axis Tumours (HPAT) Using Multi-site Video Conferencing
aEndocrinology Department, Great Ormond Street Hospital for Children, London, UK; bDepartment of Neurology and Neurosurgery University College London Hospital, London, UK; cNeurosurgery Department Great Ormond Street Hospital for Children NHS Trust, London, UK; dOncology Department University College London Hospital, London, UK; eNeuroradiology Department Great Ormond Street Hospital for Children NHS Trust, London, UK; fDepartment of Paediatric Endocrinology, Alder Hey Children’s Hospital, Liverpool, UK; gDepartment of Paediatric Endocrinology, Royal Manchester Children’s Hospital, Manchester, UK; hThe School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; iHaematology and Oncology Department, Great Ormond Street Hospital NHS Trust, London, UK; jDepartment of Endocrinology, Barts and the London School of Medicine, Queen Mary University of London, London, UK
hrp0089p1-p194
Long Term Reversibility of Presumed ACTH Deficiency (ACTHd) in Children and Young People (CYP) with Intracranial Germ Cell Tumours (IGCT)
London Centre for Paediatric Endocrinology, Neuroendocrine Division, Great Ormond Street (GOSH) and University College (UCLH) Hospitals, London, UK
hrp0089p1-p195
Endocrine Follow-up of Children with a History of Brain Tumour: Data from Our Large Cohort at Necker University Hospital, Paris, 2010-2015
aService D’Endocrinologie, Diabétologie et Gynécologie Pédiatriques, Hôpital Universitaire Necker -- Enfants Malades, Paris, France; bESPE -- Clinical Fellowship, Paris, France; cCentre De référence des Maladies Endocriniennes Rares de la Croissance (CRMERC), Paris, France; dUniversité Paris Descartes, Paris, France; eInstitut Gustave Roussy, Villejuif, France; fService de Neurochirurgie, Hôpital Universitaire Necker-Enfants Malades, Paris, France; gService d’Endocrinologie et Médecine de la Reproduction, Hôpital Universitaie La Ptié-Salpêtrière, Paris, France; hInstitut Curie, Paris, France; iCHU Montpellier, Hôpital Gui de Chauliac, Unité de Neurochirurgie Pédiatrique, Montpellier, France; jHôpital Femme Mère Enfant - HCL, Lyon, France; kService d’Endocrinologie Pédiatrique, Hôpital Universitaire Trousseau, Paris, France. lService d’Endocrinologie et DIabétologie Pédiatrique, CH André Mignot, Le Chesnay, France; mSIREDO Oncology Center (Care, Innovon and Research for Children ad AYA Cancer), Paris, France; nPSL Research University, Paris, France; oCentre de référence des Maladies Endocriniennes Rares de la Croissance (CRMERC), Villejuif, France; pInstitut Imagine (Rare Genetic diseases) Affiliate, Paris, France
hrp0089p1-p196
A Single Centre Experience of Managing a Series of Childhood Macro/Giant-Prolactinoma
aEndocrinology Department, Great Ormond Street Hospital for Children, London, UK; bNeuroradiology Department Great Ormond Street Hospital for Children, London, UK; cNeurosurgery Department Great Ormond Street Hospital for Children, London, UK; dDepartment of Oncology University College London Hospitals, London, UK; eDepartment of Endocrinology, William Harvey Research Institute, Barts and the London; School of Medicine, Queen Mary University of London, London, UK
hrp0089p1-p197
A National UK Guideline for Managing Pituitary Adenomas in Children and Young People Under 19 Years Developed According to the AGREE II Framework
aAlder Hey Children’s Hospital, Liverpool, UK; bBarts and the London School of Medicine, Queen Mary University of London, London, UK; cGreat Ormond Street Hospital and University College London Hospital, London, UK
hrp0089p1-p198
Growth Hormone Deficiency and Cryptorchidism in a Family with Xq26.3 Duplication and Position Effect on SOX3
aDepartment of Paediatric Endocrinology and Diabetology, University Children’s Hospital of Dresden, Dresden, Germany; bInstitute of Genetics, University of Dresden, Dresden, Germany; cInsitute of Genetics, University of Dresden, Dresden, Germany; dDepartment of Neuropaediatrics, University Hospital Dresden, Technische Universität Dresden, Dresden, Germany
hrp0089p1-p199
Anastrozole is Safe as Monotherapy in Early Maturing Girls with Compromised Growth, Further Improving Gain in Predicted Adult Height by the Initial Combination Therapy of an LHRH Analogue and an Aromatase Inhibitor: Results from the 'Gail' Study ISRCTN11469487
aDepartment of Pediatric – Adolescent Endocrinology and Diabetes, Athens Medical Center, Athens, Greece; bDivision of Pediatric Endocrinology, Third Department of Pediatrics, ‘Attikon’ University Hospital, Haidari, Greece; cThird Department of Pediatrics, Aristotle University of Thessaloniki, Hippokrateion General Hospital, Thessaloniki, Greece; dThird Department of Pediatrics, ‘Attikon’ University Hospital, Haidari, Greece; eEndocrine Unit, Aretaieion University Hospital, Athens, Greece
hrp0089p1-p201
Long-acting Octeotride Treatment in Children with Neurofibromatosis Type 1 - Optic Pathway Tumors and Growth Hormone Excess
aPediatric Endocrinology Unit, Institut de Recerca Pediàtrica Hospital Sant Joan de Déu, Barcelona, Spain; bPediatric Oncology Unit Sant Joan de Déu Hospital, Barcelona, Spain; cPediatric Ophtalmology Unit, Barcelona, Spain
hrp0089p1-p202
Serum Concentrations of the Endocrine Disruptors-organochlorine Pesticides (OCPs) in Greek Children with Neurodevelopmental Disorders
aFirst Department of Pediatrics, School of Medicine, ‘Aghia Sophia’ Children’s Hospital, National and Kapodistrian University of Athens, Athens, Greece; bPrince Mutaib Chair for Biomarkers of Osteoporosis, Biochemistry Department, College of Science, King Saud University, Riyadh, Saudi Arabia
hrp0089p1-p203
A Paternally Inherited Familial Precocious Puberty Caused by a Novel MKRN3 Frameshift Variant
aRoyal Cornwall Hospital, Truro, UK; bBristol Royal Hospital for Children, Bristol, UK; cRoyal Devon and Exeter Hospital, Exeter, UK
hrp0089p1-p205
Urinary Gonadotropins as a Useful Non-invasive Marker of Central Precocious Puberty
Department of Pediatrics, Hallym University Medical Center, Hallym University College of Medicine, Seoul, Republic of Korea
hrp0089p1-p207
Testicular Development and Puberty in Boys with Duchenne Muscular Dystrophy: Results From the ScOT-DMD Study
aDevelopmental Endocrinology Research Group, University of Glasgow, Glasgow, UK; bSchool of Medicine, University of Glasgow, Glasgow, UK; cPaediatric Neurosciences Research Group, Royal Hospital for Children, Glasgow, UK; dScottish Muscle Network, Queen Elizabeth University Hospital, Glasgow, UK
hrp0089p1-p208
Exposure to BPA and Phthalates and Timing of Puberty in Girls
aD.P.U.O, Bambino Gesù Children’s Hospital, Rome, Italy; bTor Vergata University of Rome, Rome, Italy; cItalian National Institute of Health, Rome, Italy; dInstitute of Clinical Physiology, CNR, Pisa, Italy; eDepartment of Women’s and Children’s Health, Karolinska Institutet, Stockolm, Sweden
hrp0089p1-p209
Hypothalamic-pituitary-testicular Axis Response to Sub-maximal Aerobic Exercise, in Pre- and Early- Pubertal Normal Weight and Obese Boys
aEndocrine Unit, “Aretaieion” Hospital, National and Kapodistrian University of Athens - Faculty of Medicine, Athens, Greece; bFirst Department of Pediatrics, “Aghia Sophia” Children’s Hospital, National and Kapodistrian University of Athens - Faculty of Medicine, Athens, Greece; cDepartment of Physical Education and Sports Sciences, Democritus University of Thrace, Komotini, Greece; dPediatric Endocrine Unit, Third Department of Pediatrics, Aristotle University of Thessaloniki, School of Medicine, “Hippokrateion” General Hospital of Thessaloniki, Thessaloniki, Greece; eDepartment of Physical Education and Sports Sciences, University of Thessaly, Trikala, Greece
hrp0089p1-p210
Effect of Pubertal Blockade and Cross-sex Hormone Treatment on the Growth Spurt in Young Transgender Adolescents: A First Report
Paediatric and Adolescent Endocrinology, University College London Hospital, London, UK
hrp0089p1-p211
Real-World Safety Data in a Cohort of Children with Noonan Syndrome Treated with GH: Final Results from NordiNet International Outcome Study (IOS) and ANSWER Program
aDepartment of Clinical Science, University of Bergen, Bergen, Norway; bDepartment of Paediatrics, Institute of Clinical Science, University of Gothenburg, Gothenburg, Sweden; cPediatric Endocrinology and Diabetes, Children’s Minnesota, Saint Paul, MN, USA; dEpidemiology, Novo Nordisk A/S, Søborg, Denmark; eGlobal Medical Affairs, Novo Nordisk Health Care AG, Zurich, Switzerland; fDepartment of Pediatrics, New York Medical College, Valhalla, New York, NY, USA
hrp0089p1-p212